Recursion Reports Interim Phase 1 Clinical Data For REC-617 Monotherapy, A Potential Best-In-Class CDK7 Inhibitor, With Encouraging Patient Response And Favorable Tolerability
Recursion Reports Interim Phase 1 Clinical Data For REC-617 Monotherapy, A Potential Best-In-Class CDK7 Inhibitor, With Encouraging Patient Response And Favorable Tolerability . (MENAFN - GlobeNewsWire - Nasdaq)    REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker ...
América - MenaFN
Jordania
https://menafn.com/images/Menafn_SmallLogo.jpg
https://menafn.com/1108973616/Recursion-Reports-Interim-Phase-1-Clinical-Data-For-REC-617-Monotherapy-A-Potential-Best-In-Class-CDK7-Inhibitor-With-Encouraging-Patient-Response-And-Favorable-Tolerability
2024-12-09
rss
(MENAFN - GlobeNewsWire - Nasdaq)    REC-617, a precision designed molecule, demonstrated dose-linear pharmacokinetics (PK) with rapid absorption and robust pharmacodynamic (PD) biomarker ...
Recursion Reports Interim Phase 1 Clinical Data For REC-617 Monotherapy, A Potential Best-In-Class CDK7 Inhibitor, With Encouraging Patient Response And Favorable Tolerability